Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of November 2024, specifically dated November 27, 2024. The report details the entry into a material contract by Haoxi Health Technology Limited, a foreign private issuer based in Beijing, China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure transaction rather than operational financial performance.
Material Changes
On November 27, 2024, the Company entered into a Warrant Exchange Agreement with holders of 3,998,000 Series A warrants. Key terms include:
- Warrants Surrendered: 3,998,000 Series A warrants (issued September 20, 2024).
- Exercise Price: $0.60 per share.
- Shares Issued: 19,990,000 Class A ordinary shares issued in exchange for the surrendered warrants.
- Legal Basis: The issuance was conducted under the Section 3(a)(9) exemption of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are discussed beyond the standard disclaimer that the summary is subject to the full text of the Exchange Agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the Exchange Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized here.
- Confirm the impact of the 19,990,000 new shares on total outstanding share count and potential dilution.
- Review the original Form F-1 (File No. 333-280174) to understand the initial terms of the Series A warrants issued in September 2024.